

Funded by NIEHS EHS Core Center Grant #P30ES020957



LEGACY AND EMERGING HALOGENATED POLLUTANTS MODULATE GUT MICROBIOTA AND ACCELERATE ATHEROSCLEROSIS



Michael Petriello, Ph.D., Wayne State University

Acknowledgments

•Petriello Lab •Dr. Katherine Roth •Dr. Zhao Yang Manisha Agarwal •Rahul Sharma •Dr. Wanging Liu •Zheyun Peng •Ze Long •Lumigen Instrument Center Mass Spectrometry Core •Dr. Johnna Birbeck •Dr. Judy Westrick

•Dr. Todd Lydic









National Institute of Environmental Health Sciences Superfund Research Program



- Background
 - Atherosclerosis and CVD
- Dioxin-like pollutants
- Per and polyfluoroalkyl substances

Heart disease risk over time



"The sweeping geographic changes in heart disease mortality observed over a relatively short period of time...suggest that systematic changes may have occurred in a variety of biomedical, behavioral, and <u>socioenvironmental factors</u>. The accompanying regional disparities...highlight the importance of <u>identifying conditions that are contributing to these</u> <u>disparities</u>".



DOI: (10.1161/CIRCULATIONAHA.115.018663)







Detroit is a highly polluted industrial city















Mechanistic toxicologists interacting with community engagement experts

What determines cardiovascular risk?



Development and progression of Atherosclerosis



Funded by NIEHS EHS Core Center Grant #P30ES020957

Causative or associative biomarkers of atherosclerosis

Lipid markers of atherosclerosis:

- Total Cholesterol, VLDL, LDL, HDL
- Triglycerides
- Apolipoproteins

Markers of Inflammation:

- C-reactive protein
- IL-1β and other cytokines
- Vascular adhesion molecules and other proteins

Emerging markers:

• Trimethylamine N-oxide





https://www.medscape.com/viewarticle/869226 https://www.hookinsmedicine.oro/health/healthy heart/stay healthv/3-myths-about-cholesteroi-lowerino-statin-drug

Preclinical models to study atherosclerosis



•Mouse models of hypercholesterolemia are gold standards for cardiovascular medicine.



Model to study lipophilic pollutantaccelerated atherosclerosis



Petriello et al. 2017, Toxicol Sci.

| LF Clinton-Cybulsky Atherogenic Diet | gm | kcal |
|--------------------------------------|------|-------|
| Ingredient | | |
| Corn Starch | 375 | 1500 |
| Maltodextrin 10 | 125 | 500 |
| Sucrose | 200 | 800 |
| Cellulose BW200 | 50 | 0 |
| Casein, Lactic | 200 | 800 |
| L-Cystine | 3 | 12 |
| Soybean Oil | 25 | 225 |
| Cocoa Butter | 20 | 180 |
| Cholesterol | 1.6 | 0 |
| Mineral Mix \$10021 | 10 | 0 |
| Dicalcium Phosphate | 13 | 0 |
| Calcium Carbonate | 5.5 | 0 |
| Potassium Citrate | 16.5 | 0 |
| Vitamin Mix V10001 | 10 | 40 |
| Choline Bitartrate | 2 | 0 |
| | | |
| | gm% | kcal% |
| Carbohydrate | 67.2 | 70.0 |
| Protein | 19.2 | 20.0 |
| Fat | 4.3 | 10.0 |



Model to study lipophilic pollutantaccelerated atherosclerosis

Control



PCB 126 increases lesion formation, circulating cytokines, and inflammatory mediators

Petriello Toxicological Sciences, 2017

PCB 126 treatment increases markers of cholesterol absorption



•According to the Framingham Offspring Study, people who are cholesterol hyperabsorbers are at increased risk of cardiovascular disease.

PCB 126 depletes a gut microbiota mediated metabolite of cholesterol





•The bacteria responsible for this function have mostly been classified within the Eubacterium genus

Xenobiotics and microbiota interact



•Microbiota metabolize some pollutants and pollutants can impact on bacteria health



PCB 126 modulates microbiota form



Tenericutes Verrucomicrobia

genera/species level

...and function

Hepatic Metabolomics Analysis^a

| Metabolite Category | Fold Change PCB vs. Vehicle | P-value | Pathway |
|------------------------|--------------------------------------|---------|---|
| Gut Microbiota | | | |
| Influenced Metabolites | | | |
| 5-hydroxyindoleacetate | 0.55 | <0.01 | Tryptophan metabolism |
| Retinol | 0.58 | 0.015 | Vitamin A metabolism |
| Retinal | 0.52 | <0.01 | Vitamin A metabolism |
| Hypotaurine | 0.47 | <0.01 | Methionine, cystine, SAM |
| 1-methylhistamine | 0.33 | 0.081 | Histidine metabolism |
| N-acetylarginine | 0.64 | <0.010 | Urea cycle |
| hypoxanthine | 0.79 | 0.012 | Purine metabolism |
| N-acetylphenylalanine | 0.35 | <0.010 | Phenylalanine metabolism |
| Hippurate | 0.52 | 0.067 | Benzoate metabolism |
| Creatinine | 0.52 | 0.086 | Creatine metabolism |
| Argininate | 0.72 | 0.014 | Urea cycle |
| N-oleoyltaurine | 1.74 | 0.049 | Endocannabinoid |
| O-methyltyrosine | 1.54 | 0.050 | Tyrosine metabolism |
| Urate | 2.13 | <0.01 | Purine metabolism |
| dimethylglycine | 1.41 | 0.022 | Glycine, serine, and threonine metabolism |
| glutarate | 1.79 | 0.097 | Fatty acid, dicarboxylate |

Are there circulating metabolites we can use as biomarkers in humans?

Funded by NIEHS EHS Core Center Grant #P30ES020957

^a n=6 per group, statistically significant differences determined by Welch's two-sample t-tests.

TMAO – an Emerging Biomarker of CVD





•Increased plasma levels of TMAO were associated with an increased risk of a major adverse cardiovascular event.

•N Engl J Med. 2013 Apr 25; 368(17): 1575–1584.

Exposure to Dioxin-like PCBs Increased Diet-derived TMAO



•The association between DLPs and increased TMAO was confirmed in the Anniston Community Health Survey.

Petriello et al. 2018, Environ Res.



Petriello et al. 2016, JNB.

CURES IN THE COMMUNITY

•Wayne State Health Mobile Unit offered lead and Covid testing and wellness checks

•Detroit Health Department administered Covid-19

vaccines

• **E-Chats** working with Urban Neighborhood Initiatives. <u>PFAS</u>, lead, and air pollution are hot topics.









ESI Webinar May 2022



- Background
 - Atherosclerosis and CVD
- Dioxin-like pollutants
- Per and polyfluoroalkyl substances

Background

- Per- and Polyfluorinated Alkyl Substances (PFAS)
 - Hydrophilic functional group + Hydrophobic tail
 - Functional groups commonly are carboxylate and sulfonates
- "Forever Chemicals"
- Over 4000 different PFAS



https://www.wateronline.com/doc/the-microplastics-and-pfas-connection-0001

 PFAS used in a variety of common industrial and consumer products including carpets, cookware, food packaging, fire fighting foams.





Teflon and Scotchgard

PFAS Subtypes and Structure

<u>Legacy</u>



Perfluorooctanoic acid

Alternative



PFHxS Tridecafluorohexane-1-sulfonic acid

Emerging



GenX Ammonium perfluoro(2-methyl-3-oxahexanoate)



PFOS Perfluorooctane sulfonate



PFNA Perfluorononanoic acid

*PFOS alternative

PFAS Levels in Humans and the Environment



PFAS concentrations in environmental water sources range from pg/L to µg/L



https://cals.ncsu.edu/applied-ecology/news/pfas-in-yadkin-pee-dee-river-food-chain/

PFAS and cardiovascular diseases

American Journal of Epidemiology



Association of Perfluorooctanoic Acid and Perfluorooctane Sulfonate With Serum Lipids Among Adults Living Near a Chemical Plant Kyle Steenland, Sarah Tinker, Stephanie Frisbee, Alan Ducatman, Viola Vaccarino

American Journal of Epidemiology, Volume 170, Issue 10, 15 November 2009, Pages 1268–1278, https://doi-org.proxy.lib.wayne.edu/10.1093/aje/kwp279

- Residential communities exposed to environmental PFAS contamination from a chemical plant in West Virginia
- Total cholesterol showed significant increasing trends by increasing decile of both PFOA and PFOS



Distribution of LDL cholesterol among NHANES subjects 2003-2016.



"LDL cholesterol (mg/dl) was adjusted for age, sex, ethnicity, and an index indicating survey wave. The deciles were determined for PFOA or PFOA based on the distribution of values after adjusting for age, sex, ethnicity, and an index indicating survey wave and calculated using the sampling parameters."

PFAS and cholesterol



In <u>humans</u>, PFAS exposure associated with <u>INCREASED cholesterol</u> levels.



However, historically, PFAS exposure <u>DECREASED</u> <u>cholesterol</u> levels in <u>rodent</u> studies.

Rodent studies

Why don't our animal models mirror impacts on cholesterol levels seen in humans?

- <u>Diet?</u>
- Genetic differences (PPARα)?
- Single exposure vs. mixture?
- Length of exposure?
- Differences in cholesterol fractions?



*More recent studies using hPPAR α and HFD-feeding <u>have</u> found elevated serum cholesterol in PFAS-exposed mice.

PFAS mixture study design



•Exposure to this PFAS mixture resulted in circulating PFAS concentrations in the ug/mL range, similar to occupational exposures.

A mouse model of PFAS mixtureincreased circulating cholesterol



```
Katherine Roth<sup>a</sup>, Zhao Yang<sup>a</sup>, Manisha Agarwal<sup>a,b</sup>, Wendy Liu<sup>c</sup>, Zheyun Peng<sup>d</sup>, Ze Long<sup>d</sup>, Johnna Birbeck<sup>e</sup>, Judy Westrick<sup>e</sup>, Wanqing Liu<sup>b,d</sup>, Michael C. Petriello<sup>a,b,*</sup>
```

•PFAS increased circulating cholesterol and bile acids and hepatic injury.

•PFAS-exposed females displayed increased lobular and portal inflammation compared to the males.

•Hepatic and circulating levels of PFOA were increased in exposed females compared to males.

